Top 10 prostate cancer articles of 2016
These are Urology Times' most-read prostate cancer articles of 2016.
The debate over PSA screening remained a key topic in prostate cancer this year. Other topics that resonated with you included biomarkers and genomic tests, active surveillance, and the first randomized trial comparing robotic and open radical prostatectomy. Here are Urology Times' most-read prostate cancer articles of 2016:
Markers redefining prostate cancer care
In this interview, Daniel W. Lin, MD, of the Washington, Seattle discusses the practical use of currently available molecular and genomic tests, cost and reimbursement considerations, the role of MRI, and what the future holds for biomarkers.
Can BPH and prostate cancer be prevented?
Benign prostatic hyperplasia (BPH) and prostate cancer are two of the most common and costly diseases of older men
Study: PCa genomic test reduces decisional conflict
For men with high-risk pathology at radical prostatectomy, exposure to results of a genomic test that classifies 5-year risk of metastasis reduces decisional conflict, according to findings of a prospective study presented at the American Society of Clinical Oncology annual meeting in Chicago. The research also demonstrated that information from the genomic test, Decipher, lowers provider uncertainty about treatment recommendations and alters treatment intensity recommendations.
Prostate Ca: PSA drop, active surveillance are key themes
Fusion biopsy, salvage versus adjuvant radiation therapy, and superextended versus extended pelvic lymph node dissection are also covered in the take home messages on prostate cancer from the 2016 AUA annual meeting. The prostate cancer take homes were presented by Robert Abouassaly, MD, MSc, of University Hospitals Case Medical Center, Cleveland.
Robotic vs. open RP: Experts react to first randomized trial
The first published randomized controlled trial comparing robot-assisted laparoscopic prostatectomy with open radical retropubic prostatectomy was published in